{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:11:36Z","timestamp":1772781096743,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T00:00:00Z","timestamp":1572393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T00:00:00Z","timestamp":1572393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Detection of antihypertensive drugs in biological samples is an important tool to assess the adherence of hypertensive patients. Urine and serum\/plasma screenings based on qualitative results may lead to misinterpretations regarding drugs with a prolonged detectability. The aim of the present study was to develop a method that can be used for therapeutic drug monitoring (TDM) of antihypertensive drugs with focus on adherence assessment. Therefore, a method for quantification of four diuretics and four \u03b2-blockers using high-performance liquid chromatography-mass spectrometric analysis (LC-MS\/MS) of combined acidic and basic serum extracts was developed and validated. The method was applied to 40 serum samples from 20 patients in a supervised medication setting (trough and peak serum samples). Literature data on therapeutic concentration ranges, as well as dose-related drug concentrations (calculated from data of pharmacokinetic studies) were used to evaluate adherence assessment criteria. Concentrations were measured for bisoprolol (n\u2009=\u20099 patients), metoprolol (n\u2009=\u20097), nebivolol (n\u2009=\u20091), canrenone (n\u2009=\u20092, metabolite of spironolactone), hydrochlorothiazide (n\u2009=\u200910) and torasemide (n\u2009=\u20098). The measured concentrations were within the therapeutic reference ranges, except for 24% of the samples (mainly \u03b2-blockers). In contrast, all measured concentrations were above the lower dose-related concentration (DRC), which appears superior in evaluating adherence. In conclusion, the quantitative analysis of antihypertensive drugs in serum samples and its evaluation on the basis of the individually calculated lower DRC is a promising tool to differentially assess adherence. This method could possibly detect a lack of adherence or other causes of insufficient therapy more reliably than qualitative methods.<\/jats:p>","DOI":"10.1038\/s41598-019-52164-y","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T20:29:05Z","timestamp":1572467345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Evaluation of the dose-related concentration approach in therapeutic drug monitoring of diuretics and \u03b2-blockers \u2013 drug classes with low adherence in antihypertensive therapy"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6718-2692","authenticated-orcid":false,"given":"Sabrina","family":"Ritscher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena","family":"Hoyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cora","family":"Wunder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Oberm\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1774-3201","authenticated-orcid":false,"given":"Stefan W.","family":"Toennes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,30]]},"reference":[{"key":"52164_CR1","unstructured":"Robert Koch-Institute. Health in Germany \u2013 the most important trends. Available at, https:\/\/www.rki.de\/EN\/Content\/Health_Monitoring\/Health_Reporting\/HealthInGermany\/Health-in-Germany_most_important_developments.pdf?__blob=publicationFile (2016)."},{"key":"52164_CR2","unstructured":"Wilkins, E. et al. European Cardiovascular Disease Statistics 2017. European Heart Network, 1\u2013192 (2017)."},{"key":"52164_CR3","unstructured":"Sabat\u00e9, E. Adherence to long-term therapies. Evidence for action. Available at, https:\/\/www.who.int\/chp\/knowledge\/publications\/adherence_full_report.pdf?ua=1 (2003)."},{"key":"52164_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10198-013-0554-4","volume":"16","author":"FS Mennini","year":"2015","unstructured":"Mennini, F. S. et al. Cost of poor adherence to anti-hypertensive therapy in five European countries. The European journal of health economics 16, 65\u201372, https:\/\/doi.org\/10.1007\/s10198-013-0554-4 (2015).","journal-title":"The European journal of health economics"},{"key":"52164_CR5","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1161\/CIRCULATIONAHA.110.983874","volume":"123","author":"IM Kronish","year":"2011","unstructured":"Kronish, I. M. et al. Meta-Analysis: Impact of Drug Class on Adherence to Antihypertensives. Circulation 123, 1611\u20131621, https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.983874 (2011).","journal-title":"Circulation"},{"key":"52164_CR6","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1161\/HYPERTENSIONAHA.116.08729","volume":"69","author":"P Gupta","year":"2017","unstructured":"Gupta, P. et al. Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension 69, 1113\u20131120, https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.08729 (2017).","journal-title":"Hypertension"},{"key":"52164_CR7","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/S0149-2918(99)80026-5","volume":"21","author":"KC Farmer","year":"1999","unstructured":"Farmer, K. C. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clinical therapeutics 21, 1074\u20131090, https:\/\/doi.org\/10.1016\/S0149-2918(99)80026-5 (1999).","journal-title":"Clinical therapeutics"},{"key":"52164_CR8","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/HJH.0b013e32835e2286","volume":"31","author":"O Jung","year":"2013","unstructured":"Jung, O. et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. Journal of hypertension 31, 766\u2013774, https:\/\/doi.org\/10.1097\/HJH.0b013e32835e2286 (2013).","journal-title":"Journal of hypertension"},{"key":"52164_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-016-0697-7","volume":"18","author":"P Gupta","year":"2016","unstructured":"Gupta, P. et al. How to Screen for Non-Adherence to Antihypertensive Therapy. Current hypertension reports 18, 89, https:\/\/doi.org\/10.1007\/s11906-016-0697-7 (2016).","journal-title":"Current hypertension reports"},{"key":"52164_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jchromb.2018.04.038","volume":"1089","author":"POM Gundersen","year":"2018","unstructured":"Gundersen, P. O. M., Helland, A., Spigset, O. & Hegstad, S. Quantification of 21 antihypertensive drugs in serum using UHPLC-MS\/MS. Journal of chromatography. B 1089, 84\u201393, https:\/\/doi.org\/10.1016\/j.jchromb.2018.04.038 (2018).","journal-title":"Journal of chromatography. B"},{"key":"52164_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke, C. et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 51, 9\u201362, https:\/\/doi.org\/10.1055\/s-0043-116492 (2018).","journal-title":"Pharmacopsychiatry"},{"key":"52164_CR12","unstructured":"Peters, F. T. et al. Requirements for the validation of analytical methods. Appendix B: To the GTFCh Guidelines for quality assurance in forensic-toxicological analyses. Available at, https:\/\/www.gtfch.org\/cms\/images\/stories\/files\/Appendix%20B%20GTFCh%2020090601.pdf (2009)."},{"key":"52164_CR13","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/aheh.19930210603","volume":"21","author":"M Kolb","year":"1993","unstructured":"Kolb, M., Bahr, A., Hippich, S. & Schulz, W. Calculation of Detection Limit, Identification Limit and Determination Limit according to DIN 32645 with the Aid of a Computer Programs. Acta hydrochim. hydrobiol. 21, 308\u2013311, https:\/\/doi.org\/10.1002\/aheh.19930210603 (1993).","journal-title":"Acta hydrochim. hydrobiol."},{"key":"52164_CR14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jpba.2009.12.012","volume":"52","author":"F Gao","year":"2010","unstructured":"Gao, F. et al. Simultaneous quantitation of hydrochlorothiazide and metoprolol in human plasma by liquid chromatography-tandem mass spectrometry. Journal of pharmaceutical and biomedical analysis 52, 149\u2013154, https:\/\/doi.org\/10.1016\/j.jpba.2009.12.012 (2010).","journal-title":"Journal of pharmaceutical and biomedical analysis"},{"key":"52164_CR15","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jpba.2010.03.004","volume":"52","author":"DI Sora","year":"2010","unstructured":"Sora, D. I., Udrescu, S., Albu, F., David, V. & Medvedovici, A. Analytical issues in HPLC\/MS\/MS simultaneous assay of furosemide, spironolactone and canrenone in human plasma samples. Journal of pharmaceutical and biomedical analysis 52, 734\u2013740, https:\/\/doi.org\/10.1016\/j.jpba.2010.03.004 (2010).","journal-title":"Journal of pharmaceutical and biomedical analysis"},{"key":"52164_CR16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1365\/s10337-004-0427-1","volume":"60","author":"K-H Liu","year":"2004","unstructured":"Liu, K.-H. et al. Simple and Sensitive Assay of Torasemide in Human Plasma by High-Performance Liquid Chromatography Using a Monolithic Silica Column. Chromatographia 60, 639\u2013643, https:\/\/doi.org\/10.1365\/s10337-004-0427-1 (2004).","journal-title":"Chromatographia"},{"key":"52164_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/cc11441","volume":"16","author":"M Schulz","year":"2012","unstructured":"Schulz, M., Iwersen-Bergmann, S., Andresen, H. & Schmoldt, A. Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics. Critical Care 16, 1\u2013134, https:\/\/doi.org\/10.1186\/cc11441 (2012).","journal-title":"Critical Care"},{"key":"52164_CR18","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3109\/15563659709043365","volume":"35","author":"MR Repetto","year":"1997","unstructured":"Repetto, M. R. & Repetto, M. Therapeutic, Toxic, and Lethal Concentrations in Human Fluids of 90 Drugs Affecting the Cardiovascular and Hematopoietic Systems. Clinical Toxicology 35, 345\u2013351, https:\/\/doi.org\/10.3109\/15563659709043365 (1997).","journal-title":"Clinical Toxicology"},{"key":"52164_CR19","doi-asserted-by":"publisher","first-page":"A1819","DOI":"10.1016\/S0735-1097(18)32360-X","volume":"71","author":"H Salem","year":"2018","unstructured":"Salem, H. et al. Worldwide Prevalence of Hypertension: A Pooled Meta-Analysis of 1670 Studies In 71 Countries With 29.5 Million Participants. Journal of the American College of Cardiology 71, A1819, https:\/\/doi.org\/10.1016\/S0735-1097(18)32360-X (2018).","journal-title":"Journal of the American College of Cardiology"},{"key":"52164_CR20","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1161\/CIRCRESAHA.116.304723","volume":"116","author":"K Rahimi","year":"2015","unstructured":"Rahimi, K., Emdin, C. A. & MacMahon, S. The epidemiology of blood pressure and its worldwide management. Circulation research 116, 925\u2013936, https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.304723 (2015).","journal-title":"Circulation research"},{"key":"52164_CR21","doi-asserted-by":"publisher","unstructured":"Schmieder, R. E. et al. Adherence to Antihypertensive Medication in Treatment-Resistant Hypertension Undergoing Renal Denervation. Journal of the American Heart Association 5; https:\/\/doi.org\/10.1161\/JAHA.115.002343 (2016).","DOI":"10.1161\/JAHA.115.002343"},{"key":"52164_CR22","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/00005344-199729002-00002","volume":"29","author":"M Barchielli","year":"1997","unstructured":"Barchielli, M. et al. Clinical Pharmacokinetics of Lercanidipine. Journal of Cardiovascular Pharmacology 29, S1\u2013S15, https:\/\/doi.org\/10.1097\/00005344-199729002-00002 (1997).","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"52164_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0378-4347(84)80210-8","volume":"308","author":"CH Kleinbloesem","year":"1984","unstructured":"Kleinbloesem, C. H., van Harten, J., van Brummelen, P. & Breimer, D. D. Liquid chromatographic determination of nifedipine in plasma and of its main metabolite in urine. Journal of Chromatography B: Biomedical Sciences and Applications 308, 209\u2013216, https:\/\/doi.org\/10.1016\/0378-4347(84)80210-8 (1984).","journal-title":"Journal of Chromatography B: Biomedical Sciences and Applications"},{"key":"52164_CR24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/jps.2600710226","volume":"71","author":"RH Barbhaiya","year":"1982","unstructured":"Barbhaiya, R. H., Craig, W. A., Perri Corrick-West, H. & Welling, P. G. Pharmacokinetics of Hydrochlorothiazide in Fasted and Nonfasted Subjects: A Comparison of Plasma Level and Urinary Excretion Methods. Journal of Pharmaceutical Sciences 71, 245\u2013248, https:\/\/doi.org\/10.1002\/jps.2600710226 (1982).","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"52164_CR25","doi-asserted-by":"crossref","unstructured":"Schwabe, U., Paffrath, D., Ludwig, W.-D. & Klauber, J. Arzneiverordnungs-Report 2018 (Springer Berlin Heidelberg, Berlin, Heidelberg, 2018).","DOI":"10.1007\/978-3-662-57386-0"},{"key":"52164_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/bmc.3884","volume":"31","author":"CFP Vespasiano","year":"2017","unstructured":"Vespasiano, C. F. P. et al. Bioequivalence study between a fixed-dose single-pill formulation of nebivolol plus hydrochlorothiazide and separate formulations in healthy subjects using high-performance liquid chromatography coupled to tandem mass spectrometry. Biomedical chromatography 31, 1\u20139, https:\/\/doi.org\/10.1002\/bmc.3884 (2017).","journal-title":"Biomedical chromatography"},{"key":"52164_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-199834010-00001","volume":"34","author":"H Knauf","year":"1998","unstructured":"Knauf, H. & Mutschler, E. Clinical pharmacokinetics and pharmacodynamics of torasemide. Clinical pharmacokinetics 34, 1\u201324, https:\/\/doi.org\/10.2165\/00003088-199834010-00001 (1998).","journal-title":"Clinical pharmacokinetics"},{"key":"52164_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/BF00609957","volume":"32","author":"K Sabanathan","year":"1987","unstructured":"Sabanathan, K., Castleden, C. M., Adam, H. K., Ryan, J. & Fitzsimons, T. J. A comparative study of the pharmacokinetics and pharmacodynamics of atenolol, hydrochlorothiazide and amiloride in normal young and elderly subjects and elderly hypertensive patients. European journal of clinical pharmacology 32, 53\u201360 (1987).","journal-title":"European journal of clinical pharmacology"},{"key":"52164_CR29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3109\/08037051.2015.1121706","volume":"25","author":"PA Esk\u00e5s","year":"2016","unstructured":"Esk\u00e5s, P. A. et al. Adherence to medication and drug monitoring in apparent treatment-resistant hypertension. Blood pressure 25, 199\u2013205, https:\/\/doi.org\/10.3109\/08037051.2015.1121706 (2016).","journal-title":"Blood pressure"},{"key":"52164_CR30","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s00392-015-0905-5","volume":"104","author":"S Ewen","year":"2015","unstructured":"Ewen, S. et al. Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine\/plasma toxicological analysis. Clinical Research in Cardiology 104, 1097\u20131105, https:\/\/doi.org\/10.1007\/s00392-015-0905-5 (2015).","journal-title":"Clinical Research in Cardiology"},{"key":"52164_CR31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/00007691-200302000-00007","volume":"25","author":"M Gex-Fabry","year":"2003","unstructured":"Gex-Fabry, M., Balant-Gorgia, A. E. & Balant, L. P. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Therapeutic drug monitoring 25, 46\u201353 (2003).","journal-title":"Therapeutic drug monitoring"},{"key":"52164_CR32","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/08037051.2019.1599814","volume":"28","author":"C Wunder","year":"2019","unstructured":"Wunder, C. et al. Adherence to antihypertensive drug treatment in patients with apparently treatment-resistant hypertension in the INSPiRED pilot study. Blood pressure 28, 168\u2013172, https:\/\/doi.org\/10.1080\/08037051.2019.1599814 (2019).","journal-title":"Blood pressure"},{"key":"52164_CR33","unstructured":"Food and Drug Administration. International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceuticals for Human use, Validation of Analytical Procedures: Methodology, ICH Q2B (Geneva, 1996)."},{"key":"52164_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/BF00609750","volume":"13","author":"JD Fitzgerald","year":"1978","unstructured":"Fitzgerald, J. D., Ruffin, R., Smedstad, K. G., Roberts, R. & McAinsh, J. Studies on the pharmacokinetics and pharmacodynamics of atenolol in man. European journal of clinical pharmacology 13, 81\u201389, https:\/\/doi.org\/10.1007\/BF00609750 (1978).","journal-title":"European journal of clinical pharmacology"},{"key":"52164_CR35","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/cpt1979254408","volume":"25","author":"WD Mason","year":"1979","unstructured":"Mason, W. D., Winer, N., Kochak, G., Cohen, I. & Bell, R. Kinetics and absolute bioavailability of atenolol. Clinical Pharmacology & Therapeutics 25, 408\u2013415, https:\/\/doi.org\/10.1002\/cpt1979254408 (1979).","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"52164_CR36","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1177\/0091270006291626","volume":"46","author":"D Jovanovi\u0107","year":"2006","unstructured":"Jovanovi\u0107, D., Cusi\u0107, S., Ranci\u0107, D., Srni\u0107, D. & Perkovi\u0107-Vukcevi\u0107, N. A pharmacokinetic comparison of generic tablets containing bisoprolol with the innovator formulation in healthy volunteers. Journal of clinical pharmacology 46, 1217\u20131222, https:\/\/doi.org\/10.1177\/0091270006291626 (2006).","journal-title":"Journal of clinical pharmacology"},{"key":"52164_CR37","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2165\/00003088-198713020-00003","volume":"13","author":"W Kirch","year":"1987","unstructured":"Kirch, W. et al. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. Clinical pharmacokinetics 13, 110\u2013117, https:\/\/doi.org\/10.2165\/00003088-198713020-00003 (1987).","journal-title":"Clinical pharmacokinetics"},{"key":"52164_CR38","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2165\/00003088-198005020-00004","volume":"5","author":"L Jord\u00f6","year":"1980","unstructured":"Jord\u00f6, L. et al. Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. Clinical pharmacokinetics 5, 169\u2013180, https:\/\/doi.org\/10.2165\/00003088-198005020-00004 (1980).","journal-title":"Clinical pharmacokinetics"},{"key":"52164_CR39","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.jpba.2008.12.031","volume":"49","author":"P Senthamil Selvan","year":"2009","unstructured":"Senthamil Selvan, P. & Pal, T. K. Chromatography-tandem mass spectrometry method for the simultaneous quantitation of metoprolol succinate and simvastatin in human plasma. Journal of pharmaceutical and biomedical analysis 49, 780\u2013785, https:\/\/doi.org\/10.1016\/j.jpba.2008.12.031 (2009).","journal-title":"Journal of pharmaceutical and biomedical analysis"},{"key":"52164_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jchromb.2008.07.040","volume":"873","author":"AK Sarkar","year":"2008","unstructured":"Sarkar, A. K. et al. Simultaneous determination of metoprolol succinate and amlodipine besylate in human plasma by liquid chromatography-tandem mass spectrometry method and its application in bioequivalence study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 873, 77\u201385, https:\/\/doi.org\/10.1016\/j.jchromb.2008.07.040 (2008).","journal-title":"Journal of chromatography. B, Analytical technologies in the biomedical and life sciences"},{"key":"52164_CR41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jchromb.2007.08.016","volume":"858","author":"PS Selvan","year":"2007","unstructured":"Selvan, P. S., Gowda, K. V., Mandal, U., Solomon, W. D. S. & Pal, T. K. Simultaneous determination of fixed dose combination of nebivolol and valsartan in human plasma by liquid chromatographic-tandem mass spectrometry and its application to pharmacokinetic study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 858, 143\u2013150, https:\/\/doi.org\/10.1016\/j.jchromb.2007.08.016 (2007).","journal-title":"Journal of chromatography. B, Analytical technologies in the biomedical and life sciences"},{"key":"52164_CR42","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s002280050237","volume":"51","author":"G Cheymol","year":"1997","unstructured":"Cheymol, G. et al. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. European journal of clinical pharmacology 51, 493\u2013498, https:\/\/doi.org\/10.1007\/s002280050237 (1997).","journal-title":"European journal of clinical pharmacology"},{"key":"52164_CR43","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/BF00608404","volume":"16","author":"U Abshagen","year":"1979","unstructured":"Abshagen, U., Besenfelder, E., Endele, R., Koch, K. & Neubert, B. Kinetics of canrenone after single and multiple doses of spironolactone. European journal of clinical pharmacology 16, 255\u2013262, https:\/\/doi.org\/10.1007\/BF00608404 (1979).","journal-title":"European journal of clinical pharmacology"},{"key":"52164_CR44","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/BF00542109","volume":"25","author":"W Krause","year":"1983","unstructured":"Krause, W., Karras, J. & Seifert, W. Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man. European journal of clinical pharmacology 25, 449\u2013453, https:\/\/doi.org\/10.1007\/BF00542109 (1983).","journal-title":"European journal of clinical pharmacology"},{"key":"52164_CR45","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/j.1365-2125.2007.03035.x","volume":"64","author":"L Haegeli","year":"2007","unstructured":"Haegeli, L. et al. Sublingual administration of furosemide: new application of an old drug. British journal of clinical pharmacology 64, 804\u2013809, https:\/\/doi.org\/10.1111\/j.1365-2125.2007.03035.x (2007).","journal-title":"British journal of clinical pharmacology"},{"key":"52164_CR46","unstructured":"Barr, W. H. et al Torasemide dose proportionality of pharmacokinetics and pharmacodynamics. Prog Pharmacol Clin Pharmacol, 29\u201337 (1990)."},{"key":"52164_CR47","first-page":"164","volume":"38","author":"G Neugebauer","year":"1988","unstructured":"Neugebauer, G., Besenfelder, E. & M\u00f6llendorff, E. von. Pharmacokinetics and metabolism of torasemide in man. Arzneimittel-Forschung 38, 164\u2013166 (1988).","journal-title":"Arzneimittel-Forschung"},{"key":"52164_CR48","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1472-8206.2008.00643.x","volume":"23","author":"MJ Barbanoj","year":"2009","unstructured":"Barbanoj, M. J. et al. Comparison of repeated-dose pharmacokinetics of prolonged-release and immediate-release torasemide formulations in healthy young volunteers. Fundamental & clinical pharmacology 23, 115\u2013125, https:\/\/doi.org\/10.1111\/j.1472-8206.2008.00643.x (2009).","journal-title":"Fundamental & clinical pharmacology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52164-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52164-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52164-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T15:06:14Z","timestamp":1671289574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52164-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,30]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["52164"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-52164-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,30]]},"assertion":[{"value":"11 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15652"}}